BNR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Burning Rock Biotech Ltd (BNR) is not a good buy at the moment for a beginner investor with a long-term strategy. The technical indicators suggest a bearish trend, the financial performance is weak with declining net income and EPS, and there are no significant positive catalysts or trading signals to support a buy decision. It is better to wait for clearer signs of recovery or positive momentum before investing.
The MACD is negative and expanding, indicating a bearish trend. The RSI is at 17.915, signaling the stock is oversold. Moving averages are converging, suggesting indecision in the market. The stock is trading below key support levels, with S1 at 24.548 and S2 at 22.837.
The gross margin increased by 5.18% YoY in Q3 2025, showing some operational efficiency improvement.
Analysts have downgraded the stock, and there are no recent positive news or significant trading trends to support a bullish sentiment.
In Q3 2025, revenue increased by 2.31% YoY, but net income dropped to -16.76M (-53.12% YoY), and EPS fell to -0.16 (-54.29% YoY). Gross margin improved to 75.1% (+5.18% YoY), but overall financial performance remains weak.
Analysts have downgraded the stock. Morgan Stanley downgraded it to Underweight with a reduced price target of EUR 50 from EUR 63. Berenberg also lowered its price target to EUR 48 from EUR 51 and maintained a Hold rating.
